NewGen BioPharma Corp.: 10-Q filed 2016-09-07
What NewGen BioPharma Corp. reported in its quarterly report filed 2016-09-07 (fiscal Q3 2016): 9 published measures, 28 facts as tagged in accession 0001640334-16-001651.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-09-07
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001640334-16-001651 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NewGen BioPharma Corp. filings.
Reported measures
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-07-31 | 104,638 | USD | |
| At 2015-10-31 | 83,305 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-07-31 | -104,638 | USD | |
| At 2015-10-31 | -83,305 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-05-01 to 2016-07-31 | -4,000 | USD | 92 |
| 2015-11-01 to 2016-07-31 | -21,333 | USD | 274 |
| 2015-05-01 to 2015-07-31 | -4,400 | USD | 92 |
| 2014-11-01 to 2015-07-31 | -19,962 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-07-31 | -170,015 | USD | |
| At 2015-10-31 | -148,682 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-05-01 to 2016-07-31 | -4,000 | USD | 92 |
| 2015-11-01 to 2016-07-31 | -21,333 | USD | 274 |
| 2015-05-01 to 2015-07-31 | -4,400 | USD | 92 |
| 2014-11-01 to 2015-07-31 | -19,962 | USD | 273 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-05-01 to 2016-07-31 | 4,000 | USD | 92 |
| 2015-11-01 to 2016-07-31 | 21,333 | USD | 274 |
| 2015-05-01 to 2015-07-31 | 4,400 | USD | 92 |
| 2014-11-01 to 2015-07-31 | 19,962 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-07-31 | 11,900,000 | shares | |
| At 2015-10-31 | 11,900,000 | shares |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-05-01 to 2016-07-31 | -4,000 | USD | 92 |
| 2015-11-01 to 2016-07-31 | -21,333 | USD | 274 |
| 2015-05-01 to 2015-07-31 | -4,400 | USD | 92 |
| 2014-11-01 to 2015-07-31 | -19,962 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-05-01 to 2016-07-31 | 1,000 | USD | 92 |
| 2015-11-01 to 2016-07-31 | 3,304 | USD | 274 |
| 2015-05-01 to 2015-07-31 | 1,400 | USD | 92 |
| 2014-11-01 to 2015-07-31 | 4,354 | USD | 273 |
Inspect the source
- Entity
- NewGen BioPharma Corp. / CIK 0001537274
- Captured
- SEC response SHA-256
d7f303f92ebc51b5c84b0c93fdae7cea7702fb134ae32e28604cb4d616f0316f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001537274.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))